Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 2017;4:595-604.

Anderson, KE, D Stamler, MD Davis, SA Factor, RA Hauser, J Isojarvi, LF Jarskog, et al. 2017. “Deutetrabenazine for Treatment of Involuntary Movements in Patients With Tardive Dyskinesia (AIM-TD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Psychiatry 2017;4:595-604.”. Lancet Psychiatry.